Hong Kong stock movement: TRANSTHERA-B rose 18.76%, with clear capital flow, market sentiment triggered volatility attention

Hong Kong Stock Movement TRANSTHERA-B, up 18.76%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Stocks Ranked High in Industry Transaction Volume BeiGene, up 1.22%. Based on recent key news: On May 8, BeiGene recorded a large transaction with a transaction amount of 28.64 million yuan, and the stock price rose by 1.1%. This transaction indicates positive market interest in the stock, driving the price up. On May 6, BeiGene announced its first-quarter financial report, with net profit increasing 178 times year-on-year, reaching 227 million USD. Strong financial performance boosted market confidence, driving the stock price up. On May 7, CICC reported that BeiGene's core product, BRUKINSA, saw global revenue growth of 39% and raised its full-year revenue guidance. This news further enhanced investors' expectations for the company's future growth. The pharmaceutical industry is performing strongly, with policy support. Kangfang Biopharma, down 2.32%. Based on recent key news: On May 5, Kangfang Biopharma recorded a large cross-trade with a transaction amount of 29.57 million yuan, and the stock price was down 2% compared to the previous closing price, leading to the price drop. On May 6, JP Morgan reported that the trial results of Kangfang Biopharma's partner Summit did not reach statistical significance, dragging down Summit's stock price and affecting market confidence in Kangfang Biopharma. On May 6, active trading in Chinese innovative drugs showed an increase in the proportion of preclinical to clinical phase I projects, reflecting market expectations and recognition of innovative drugs. Although Kangfang Biopharma's stock price fell, the industry outlook remains optimistic. Active trading in innovative drugs, with high market expectations. Innovent Biologics, down 2.31%. Based on recent news: On May 7, Innovent Biologics experienced a large transaction with a transaction amount of 29.1575 million HKD, indicating high market attention on the stock, which may lead to price volatility. On May 6, research showed that the safety of intratumoral injection of ipilimumab combined with intravenous injection of nivolumab is comparable, revealing potential mechanisms and biomarkers that may impact the company's future R&D direction. On May 5, Southwest Securities' research report pointed out that the total amount of overseas projects by Chinese innovative pharmaceutical companies has significantly increased, indicating that Chinese innovative assets have become core targets for global pharmaceutical giants' pipelines, which is of great significance for Innovent Biologics' international market layout. The innovative drug approval system is optimized, and policy support continues to strengthen. Stocks Ranked High in Industry Market Capitalization Kelun-Biotech, down 0.92%, with a market capitalization of 105.1 billion HKD, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation